Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organ systems of the body. SLE symptoms range from general malaise to serious CNS and renal manifestations. Hydroxychloroquine, corticosteroids, and conventional immunosuppressants are the mainstay treatments for SLE. Unfortunately, many patients with SLE fail to respond to these therapies and/or experience significant adverse events. In these patients, clinicians may utilize other available agents, such as the biologics Benlysta (GSK) and Rituxan (Roche; off-label). This content provides manufacturers of current treatments and developers of novel SLE agents with insights into the use of SLE drugs and into the market trends in the SLE space.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: GlaxoSmithKline, Roche, Bristol Myers Squibb
Key drugs: Benlysta, Rituxan, mycophenolate mofetil, azathioprine, cyclosporine, cyclophosphamide, hydroxychloroquine, leflunomide, methotrexate, tacrolimus, mycophenolate sodium, Orencia